WP16302 a bioequivalence study comparing ganciclovir from the valganciclovir syrup formulation and the commercial valganciclovir 450mg tablet (Valcyte) at a dose of 900mg in kidney transplant recipients, sponsor protocol dated 8/11/2005 and investigator brochure version August 2005.

Next Previous
Trial Profile

WP16302 a bioequivalence study comparing ganciclovir from the valganciclovir syrup formulation and the commercial valganciclovir 450mg tablet (Valcyte) at a dose of 900mg in kidney transplant recipients, sponsor protocol dated 8/11/2005 and investigator brochure version August 2005.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Ganciclovir; Valganciclovir
  • Indications Cytomegalic inclusion disorders
  • Focus Pharmacokinetics

    • Most Recent Events

    • 29 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top